+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Contrast Media/Contrast Agent Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 200 Pages
  • September 2024
  • Region: Global
  • Expert Market Research
  • ID: 6015981
The global contrast media/contrast agent market stood at a value of around USD 5.3 billion in 2023. The market is further expected to grow at a CAGR of 4.1% in the forecast period of 2024-2032 to attain a value of USD 7.6 billion by 2032.

Global Contrast Media/Contrast Agent Market Analysis

Contrast media, also known as contrast agents, are substances used in medical imaging to enhance the visibility of internal structures in radiographic procedures. These agents are commonly used in various imaging modalities, including X-rays, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound, to improve the diagnostic accuracy of these techniques. The global contrast media market has seen significant growth over the past few years, driven by the increasing demand for diagnostic imaging procedures and advancements in imaging technologies.

Market Drivers

Rising Prevalence of Chronic Diseases: The growing incidence of chronic diseases such as cardiovascular diseases, cancer, and neurological disorders has led to an increased demand for diagnostic imaging procedures. Contrast media play a crucial role in enhancing the quality of these imaging procedures, thus driving market growth.

Technological Advancements in Imaging Modalities: Innovations in imaging technologies, such as the development of advanced MRI and CT scanners, have increased the efficacy and safety of contrast agents. These advancements have expanded the applications of contrast media, further propelling market expansion.

Aging Population: The global increase in the elderly population has led to a higher prevalence of age-related diseases, necessitating more frequent diagnostic imaging. As a result, the demand for contrast media has surged, contributing to market growth.

Increasing Awareness and Early Diagnosis: There is a growing awareness among healthcare providers and patients about the benefits of early diagnosis of diseases. This awareness has led to an increase in the number of diagnostic imaging procedures performed, boosting the demand for contrast agents.

Challenges

Adverse Reactions and Safety Concerns: Despite their widespread use, contrast media can sometimes cause adverse reactions in patients, ranging from mild allergic reactions to severe anaphylactic shocks. These safety concerns pose a significant challenge to the market.

High Costs of Imaging Procedures: The high cost of diagnostic imaging procedures, particularly in developing countries, can limit the accessibility of these services to a broader population. This financial barrier can hinder the growth of the contrast media market.

Regulatory Hurdles: The stringent regulatory framework governing the approval and use of contrast agents can slow down the introduction of new products to the market. Compliance with these regulations is crucial but can be time-consuming and costly for manufacturers.

Environmental Concerns: The disposal of contrast media, especially those containing iodine and gadolinium, poses environmental challenges. Efforts to mitigate the environmental impact of these substances can affect market dynamics.

Future Opportunities

Development of Novel Contrast Agents: Research and development in the field of contrast media are focused on creating new agents with improved safety profiles and efficacy. The introduction of these novel agents can open new avenues for market growth.

Expansion in Emerging Markets: Emerging economies, particularly in Asia-Pacific and Latin America, offer significant growth opportunities for the contrast media market. Increasing healthcare expenditure and improving healthcare infrastructure in these regions can drive market expansion.

Personalised Medicine: The growing trend towards personalised medicine, where treatments and diagnostics are tailored to individual patients, can lead to the development of customised contrast agents. These agents can provide better imaging results and improve patient outcomes.

Integration with Artificial Intelligence (AI): The integration of AI with imaging technologies can enhance the diagnostic capabilities of contrast media. AI algorithms can help in better interpretation of imaging results, leading to more accurate diagnoses and treatment plans.

Sustainable Practices: There is an increasing focus on developing environmentally sustainable practices for the production and disposal of contrast media. Innovations in this area can address environmental concerns and promote the adoption of contrast agents.

Global Contrast media/contrast agent Market Trends

The global contrast media market is experiencing rapid growth, driven by the increasing demand for diagnostic imaging and advancements in medical technology. This market is characterised by several key trends that are shaping its future trajectory.

Market Trends

Shift Towards Non-Ionic and Low-Osmolar Contrast Agents: There is a growing preference for non-ionic and low-osmolar contrast agents due to their reduced risk of adverse reactions compared to ionic and high-osmolar agents. These agents provide better patient safety and comfort, leading to their increased adoption in clinical settings.

Rising Use of Gadolinium-Based Agents for MRI: Gadolinium-based contrast agents (GBCAs) are becoming increasingly popular for magnetic resonance imaging (MRI) due to their superior imaging capabilities. Recent developments in safer formulations and reduced dosing requirements are further boosting their usage.

Introduction of Microbubble Contrast Agents for Ultrasound: Microbubble contrast agents are gaining traction in ultrasound imaging, particularly in cardiology and oncology. These agents enhance the visualisation of blood flow and tissue structures, improving the diagnostic accuracy of ultrasound procedures.

Development of Organ-Specific Contrast Agents: Research is focused on developing contrast agents tailored for specific organs or tissues, such as liver-specific or cardiac-specific agents. These specialised agents offer enhanced imaging performance for targeted diagnostics, contributing to better patient management.

Advancements in AI and Machine Learning Integration: The integration of artificial intelligence (AI) and machine learning (ML) with imaging technologies is revolutionising the contrast media market. AI algorithms assist in the precise interpretation of imaging results, increasing the accuracy and efficiency of diagnostics.

Growing Demand in Emerging Markets: Emerging markets, especially in Asia-Pacific and Latin America, are witnessing a surge in demand for contrast media due to improving healthcare infrastructure and rising healthcare expenditure. These regions present significant growth opportunities for market players.

Global Contrast media/contrast agent Market Segmentation

Market Breakup by Type

  • Iodinated Contrast Media
  • Gadolinium-Based Contrast Media
  • Microbubble Contrast Media
  • Barium-Based Contrast Media
The global contrast media market is segmented by type into iodinated, gadolinium-based, microbubble, and barium-based contrast media. Iodinated contrast media dominate due to their widespread use in CT scans, driven by rising chronic disease prevalence. Gadolinium-based contrast media are gaining traction in MRI due to advancements in safer formulations. Microbubble contrast media are increasingly used in ultrasound imaging for cardiology and oncology. Barium-based contrast media remain essential for gastrointestinal tract imaging. Future growth in these segments is driven by technological advancements, increased diagnostic imaging demand, and the expansion of healthcare services in emerging markets, positioning these segments to propel overall market growth during the forecast period.

Market Breakup by Modality

  • X-Ray/ Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
  • Ultrasound
The global contrast media market is segmented by modality into X-ray/computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound. X-ray/CT dominates due to its extensive application in diagnosing a wide range of conditions, supported by rising chronic disease incidences. MRI, driven by advancements in gadolinium-based agents and superior imaging capabilities, is seeing significant growth. Ultrasound is increasingly adopting microbubble contrast agents for enhanced visualisation in cardiology and oncology. Technological advancements, increasing diagnostic imaging demand, and the expansion of healthcare services in emerging markets are set to drive growth in these modalities, propelling overall market expansion during the forecast period.

Market Breakup by Application

  • Cardiovascular Disorders
  • Cancer
  • Gastrointestinal Disorders
  • Musculoskeletal Disorders
  • Neurological Disorders
  • Nephrological Disorders
  • Others
The global contrast media market is segmented by application into cardiovascular disorders, cancer, gastrointestinal disorders, musculoskeletal disorders, neurological disorders, nephrological disorders, and others. Cardiovascular and cancer applications dominate due to the high prevalence of these conditions and the critical role of imaging in their diagnosis and treatment. Gastrointestinal and musculoskeletal disorders also see substantial demand for contrast media. Neurological and nephrological disorders benefit from advanced imaging technologies for precise diagnosis. Future growth is driven by increasing chronic disease incidence, technological advancements, and expanding healthcare infrastructure in emerging markets, positioning these applications to significantly drive market growth during the forecast period.

Market Breakup by Region

  • North America 
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
The global contrast media market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America leads the market due to advanced healthcare infrastructure, high diagnostic imaging demand, and ongoing technological innovations. Europe follows closely, benefiting from strong healthcare systems and significant R&D investments. Asia Pacific is poised for rapid growth, driven by increasing healthcare expenditure, expanding medical tourism, and rising chronic disease prevalence. Latin America and the Middle East and Africa show emerging potential due to improving healthcare access and infrastructure. These regional dynamics collectively drive the market's overall growth during the forecast period.

Global Contrast media/contrast agent Market Competitive Landscape

The competitive landscape of the global contrast media market features key players such as GE HealthCare, Bracco Imaging S.P.A, Bayer AG, Guerbet, Lantheus Holdings, Inc., Imax Diagnostics, TRIVITRON HEALTHCARE PRIVATE LIMITED, and Nano Therapeutics Pvt Ltd. These companies are actively engaged in market activities including mergers and acquisitions to expand their product portfolios and geographical reach. Research initiatives focus on developing safer and more effective contrast agents. Product introductions aim at enhancing imaging accuracy and patient safety. Strategic partnerships and collaborations with healthcare providers and research institutions are common to strengthen market presence and drive innovation. These activities collectively contribute to the dynamic and competitive nature of the contrast media market, fostering growth and technological advancement.

Key Questions Answered in the Report

  • What is the current and future performance of the Global Contrast media/contrast agent market?
  • What are the main challenges facing the Global Contrast media/contrast agent market?
  • What are the key drivers of the Global Contrast media/contrast agent market?
  • What emerging trends are shaping the future of the Global Contrast media/contrast agent market?
  • What drives the dominance of cardiovascular and cancer applications in the contrast media market?
  • How does Europe benefit in the contrast media market from its healthcare systems and R&D investments?
  • How do specialised organ-specific contrast agents enhance imaging performance and contribute to patient management?
  • How do environmentally sustainable practices in contrast media production and disposal address environmental concerns?
  • What are the common strategies used by key players in the Global Contrast media/contrast agent market?

Key Benefits for Stakeholders

  • The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Global Contrast media/contrast agent market from 2017-2032.
  • The research report provides the latest information on the market drivers, challenges, and opportunities in the Global Contrast media/contrast agent market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Global Contrast media/contrast agent industry and its attractiveness.
  • The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.


This product will be delivered within 5-7 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Contrast Media/Contrast Agent Market Overview
3.1 Global Contrast Media/Contrast Agent Market Historical Value (2017-2023)
3.2 Global Contrast Media/Contrast Agent Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Global Contrast Media/Contrast Agent Market Landscape*
5.1 Global Contrast Media/Contrast Agent: Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Contrast Media/Contrast Agent: Product Landscape
5.2.1 Analysis by Type
6 Global Contrast Media/Contrast Agent Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 PESTEL Analysis
6.3.1 Political
6.3.2 Environmental
6.3.3 Social
6.3.4 Technological
6.3.5 Ethical
6.3.6 Legal
6.4 Porter’s Five Forces Model
6.4.1 Bargaining Power of Suppliers
6.4.2 Bargaining Power of Buyers
6.4.3 Threat of New Entrants
6.4.4 Threat of Substitutes
6.4.5 Degree of Rivalry
6.5 Key Demand Indicators
6.6 Key Price Indicators
6.7 Industry Events, Initiatives, and Trends
6.8 Value Chain Analysis
7 Global Contrast Media/Contrast Agent Market Segmentation (2017-2032)
7.1 Global Contrast Media/Contrast Agent Market (2017-2032) by Type
7.1.1 Market Overview
7.1.2 Iodinated Contrast Media
7.1.3 Gadolinium-Based Contrast Media
7.1.4 Microbubble Contrast Media
7.1.5 Barium-Based Contrast Media
7.2 Global Contrast Media/Contrast Agent Market (2017-2032) by Modality
7.2.1 Market Overview
7.2.2 X-Ray/ Computed Tomography (CT)
7.2.3 Magnetic Resonance Imaging (MRI)
7.2.4 Ultrasound
7.3 Global Contrast Media/Contrast Agent Market (2017-2032) by Application
7.3.1 Market Overview
7.3.2 Cardiovascular Disorders
7.3.3 Cancer
7.3.4 Gastrointestinal Disorders
7.3.5 Musculoskeletal Disorders
7.3.6 Neurological Disorders
7.3.7 Nephrological Disorders
7.3.8 Others
7.4 Global Contrast Media/Contrast Agent Market (2017-2032) by Route of Administration
7.4.1 Market Overview
7.4.2 Intravenous
7.4.3 Oral Route
7.4.4 Rectal Route
7.5 Global Contrast Media/Contrast Agent Market (2017-2032) by End User
7.5.1 Market Overview
7.5.2 Hospitals
7.5.3 Diagnostic Imaging Centers
7.5.4 Others
7.6 Global Contrast Media/Contrast Agent Market (2017-2032) by Region
7.6.1 Market Overview
7.6.2 North America
7.6.3 Europe
7.6.4 Asia Pacific
7.6.5 Latin America
7.6.6 Middle East and Africa
8 North America Contrast Media/Contrast Agent Market (2017-2032)
8.1 North America Contrast Media/Contrast Agent Market (2017-2032) by Type
8.1.1 Market Overview
8.1.2 Iodinated Contrast Media
8.1.3 Gadolinium-Based Contrast Media
8.1.4 Microbubble Contrast Media
8.1.5 Barium-Based Contrast Media
8.2 North America Contrast Media/Contrast Agent Market (2017-2032) by Modality
8.2.1 Market Overview
8.2.2 X-Ray/ Computed Tomography (CT)
8.2.3 Magnetic Resonance Imaging (MRI)
8.2.4 Ultrasound
8.3 North America Contrast Media/Contrast Agent Market (2017-2032) by Application
8.3.1 Market Overview
8.3.2 Cardiovascular Disorders
8.3.3 Cancer
8.3.4 Gastrointestinal Disorders
8.3.5 Musculoskeletal Disorders
8.3.6 Neurological Disorders
8.3.7 Nephrological Disorders
8.3.8 Others
8.4 North America Contrast Media/Contrast Agent Market (2017-2032) by Route of Administration
8.4.1 Market Overview
8.4.2 Intravenous
8.4.3 Oral Route
8.4.4 Rectal Route
8.5 North America Contrast Media/Contrast Agent Market (2017-2032) by Country
8.5.1 United States of America
8.5.2 Canada
9 Europe Contrast Media/Contrast Agent Market (2017-2032)
9.1 Europe Contrast Media/Contrast Agent Market (2017-2032) by Type
9.1.1 Market Overview
9.1.2 Iodinated Contrast Media
9.1.3 Gadolinium-Based Contrast Media
9.1.4 Microbubble Contrast Media
9.1.5 Barium-Based Contrast Media
9.2 Europe Contrast Media/Contrast Agent Market (2017-2032) by Modality
9.2.1 Market Overview
9.2.2 X-Ray/ Computed Tomography (CT)
9.2.3 Magnetic Resonance Imaging (MRI)
9.2.4 Ultrasound
9.3 Europe Contrast Media/Contrast Agent Market (2017-2032) by Application
9.3.1 Market Overview
9.3.2 Cardiovascular Disorders
9.3.3 Cancer
9.3.4 Gastrointestinal Disorders
9.3.5 Musculoskeletal Disorders
9.3.6 Neurological Disorders
9.3.7 Nephrological Disorders
9.3.8 Others
9.4 Europe Contrast Media/Contrast Agent Market (2017-2032) by Route of Administration
9.4.1 Market Overview
9.4.2 Intravenous
9.4.3 Oral Route
9.4.4 Rectal Route
9.5 Europe Contrast Media/Contrast Agent Market (2017-2032) by Country
9.5.1 United Kingdom
9.5.2 Germany
9.5.3 France
9.5.4 Italy
9.5.5 Others
10 Asia Pacific Contrast Media/Contrast Agent Market (2017-2032)
10.1 Asia Pacific Contrast Media/Contrast Agent Market (2017-2032) by Type
10.1.1 Market Overview
10.1.2 Iodinated Contrast Media
10.1.3 Gadolinium-Based Contrast Media
10.1.4 Microbubble Contrast Media
10.1.5 Barium-Based Contrast Media
10.2 Asia Pacific Contrast Media/Contrast Agent Market (2017-2032) by Modality
10.2.1 Market Overview
10.2.2 X-Ray/ Computed Tomography (CT)
10.2.3 Magnetic Resonance Imaging (MRI)
10.2.4 Ultrasound
10.3 Asia Pacific Contrast Media/Contrast Agent Market (2017-2032) by Application
10.3.1 Market Overview
10.3.2 Cardiovascular Disorders
10.3.3 Cancer
10.3.4 Gastrointestinal Disorders
10.3.5 Musculoskeletal Disorders
10.3.6 Neurological Disorders
10.3.7 Nephrological Disorders
10.3.8 Others
10.4 Asia Pacific Contrast Media/Contrast Agent Market (2017-2032) by Route of Administration
10.4.1 Market Overview
10.4.2 Intravenous
10.4.3 Oral Route
10.4.4 Rectal Route
10.5 Asia Pacific Contrast Media/Contrast Agent Market (2017-2032) by Country
10.5.1 China
10.5.2 Japan
10.5.3 India
10.5.4 ASEAN
10.5.5 Australia
10.5.6 Others
11 Latin America Contrast Media/Contrast Agent Market (2017-2032
11.1 Latin America Contrast Media/Contrast Agent Market (2017-2032) by Type
11.1.1 Market Overview
11.1.2 Iodinated Contrast Media
11.1.3 Gadolinium-Based Contrast Media
11.1.4 Microbubble Contrast Media
11.1.5 Barium-Based Contrast Media
11.2 Latin America Contrast Media/Contrast Agent Market (2017-2032) by Modality
11.2.1 Market Overview
11.2.2 X-Ray/ Computed Tomography (CT)
11.2.3 Magnetic Resonance Imaging (MRI)
11.2.4 Ultrasound
11.3 Latin America Contrast Media/Contrast Agent Market (2017-2032) by Application
11.3.1 Market Overview
11.3.2 Cardiovascular Disorders
11.3.3 Cancer
11.3.4 Gastrointestinal Disorders
11.3.5 Musculoskeletal Disorders
11.3.6 Neurological Disorders
11.3.7 Nephrological Disorders
11.3.8 Others
11.4 Latin America Contrast Media/Contrast Agent Market (2017-2032) by Route of Administration
11.4.1 Market Overview
11.4.2 Intravenous
11.4.3 Oral Route
11.4.4 Rectal Route
11.5 Latin America Contrast Media/Contrast Agent Market (2017-2032) by Country
11.5.1 Brazil
11.5.2 Argentina
11.5.3 Mexico
11.5.4 Others
12 Middle East and Africa Contrast Media/Contrast Agent Market (2017-2032)
12.1 Middle East and Africa Contrast Media/Contrast Agent Market (2017-2032) by Type
12.1.1 Market Overview
12.1.2 Iodinated Contrast Media
12.1.3 Gadolinium-Based Contrast Media
12.1.4 Microbubble Contrast Media
12.1.5 Barium-Based Contrast Media
12.2 Middle East and Africa Contrast Media/Contrast Agent Market (2017-2032) by Modality
12.2.1 Market Overview
12.2.2 X-Ray/ Computed Tomography (CT)
12.2.3 Magnetic Resonance Imaging (MRI)
12.2.4 Ultrasound
12.3 Middle East and Africa Contrast Media/Contrast Agent Market (2017-2032) by Application
12.3.1 Market Overview
12.3.2 Cardiovascular Disorders
12.3.3 Cancer
12.3.4 Gastrointestinal Disorders
12.3.5 Musculoskeletal Disorders
12.3.6 Neurological Disorders
12.3.7 Nephrological Disorders
12.3.8 Others
12.4 Middle East and Africa Contrast Media/Contrast Agent Market (2017-2032) by Route of Administration
12.4.1 Market Overview
12.4.2 Intravenous
12.4.3 Oral Route
12.4.4 Rectal Route
12.5 Middle East and Africa Contrast Media/Contrast Agent Market (2017-2032) by Country
12.5.1 Saudi Arabia
12.5.2 United Arab Emirates
12.5.3 Nigeria
12.5.4 South Africa
12.5.5 Others
13 Regulatory Framework
13.1 Regulatory Overview
13.2 US FDA
13.3 EU EMA
13.4 INDIA CDSCO
13.5 JAPAN PMDA
13.6 Others
14 Patent Analysis
14.1 Analysis by Type of Patent
14.2 Analysis by Publication Year
14.3 Analysis by Issuing Authority
14.4 Analysis by Patent Age
14.5 Analysis by CPC Analysis
14.6 Analysis by Patent Valuation
14.7 Analysis by Key Players
15 Strategic Initiatives
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership and Collaborations
15.3 Analysis by Joint Ventures
15.4 Analysis by Leading Players
15.5 Analysis by Geography
16 Supplier Landscape
16.1 Market Share Analysis, By Region (Top 5 Companies)
16.1.1 Market Share Analysis: Global
16.1.2 Market Share Analysis: North America
16.1.3 Market Share Analysis: Europe
16.1.4 Market Share Analysis: Asia-Pacific
16.1.5 Market Share Analysis: Others
16.2 GE HealthCare
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.2.5 Certifications
16.3 Bracco Imaging S.P .A
16.3.1 Product Portfolio
16.3.2 Demographic Reach and Achievements
16.3.3 Mergers and Acquisitions
16.3.4 Certifications
16.4 Bayer AG
16.4.1 Financial Analysis
16.4.2 Product Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.4.5 Certifications
16.5 Guerbet
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.5.5 Certifications
16.6 Lantheus Holdings, Inc .
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.6.5 Certifications
16.7 Imax diagnostics
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisitions
16.7.5 Certifications
16.8 TRIVITRON HEALTHCARE PRIVATE LIMITED
16.8.1 Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.8.5 Certifications
16.9 Nano Therapeutics Pvt Ltd
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.9.5 Certifications
17 Global Contrast Media/Contrast Agent Market - Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)

Companies Mentioned

  • GE Healthcare
  • Bracco Imaging S.P.A
  • Bayer AG
  • Guerbet
  • Nano Therapeutics Pvt. Ltd.

Methodology

Loading
LOADING...

Table Information